Protocol Page


	Study ID (Protocol Number)
	AI452-008


	STUDY LOCATIONS*
	Alamo Medical Research San Antonio, TX 78215 Recruiting	Carolinas Center For Liver Disease Statesville, NC 28677 Recruiting
	Bristol-Myers Squibb/David E. Bernstein, Md Manhasset, NY 11030 Recruiting	Carolinas Medical Center Charlotte, NC 28203 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
	STUDY OVERVIEW
	The purpose of this study is to determine if combination therapy with Pegylated Interferon Lambda (BMS-914143) plus Ribavirin (RBV) with a single direct antiviral agent (BMS-790052 or BMS-650032) for 24 weeks is effective and safe for treatment of Chronic Hepatitis C (CHC) compared to current standard therapy with Pegylated Interferon Alpha-2a plus RBV for 48 weeks.

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.